Silence Therapeutics (NASDAQ:SLN) shares dropped 5.1% on Monday, trading below its 50- and 200-day simple moving averages. The company missed quarterly earnings and revenue expectations, reporting negative margins and return on equity. Despite a consensus “Hold” rating from analysts, institutional investors have shown mixed activity in their holdings.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1% - Here's What Happened
Silence Therapeutics (NASDAQ:SLN) shares dropped 5.1% on Monday, trading below its 50- and 200-day simple moving averages. The company missed quarterly earnings and revenue expectations, reporting negative margins and return on equity. Despite a consensus “Hold” rating from analysts, institutional investors have shown mixed activity in their holdings.